Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients.
Sahin F, Saydam G, Cömert M, Uz B, Yavuz AS, Turan E, Yönal I, Atay H, Keltikli E, Turgut M, Pehlivan M, Akay MO, Gürkan E, Paydaş S, Kahraman S, Demirkan F, Kırkızlar O, Akpınar S, Pamuk GE, Demir M, Ozbaş HM, Sönmez M, Gültürk M, Salihoğlu A, Eşkazan AE, Ar C, Haydaroğlu Şahin H, Ongören S, Başlar Z, Aydın Y, Yenere MN, Tüzüner N, Ferhanoğlu B, Haznedaroglu IC, Ilhan O, Soysal T. Sahin F, et al. Among authors: tuzuner n. Turk J Haematol. 2013 Dec;30(4):351-8. doi: 10.4274/tjh.2013.0151. Epub 2013 Dec 5. Turk J Haematol. 2013. PMID: 24385824 Free PMC article.
The Association Between JAK2V617F Mutation and Bone Marrow Fibrosis at Diagnosis in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms.
Arı MC, Büyüktaş D, Eşkazan AE, Ongören Aydın S, Tanrıkulu E, Başlar Z, Buyru AN, Ferhanoğlu B, Aydın Y, Tüzüner N, Soysal T. Arı MC, et al. Among authors: tuzuner n. Turk J Haematol. 2012 Sep;29(3):242-7. doi: 10.5505/tjh.2012.58751. Epub 2012 Oct 5. Turk J Haematol. 2012. PMID: 24744667 Free PMC article.
First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate.
Eskazan AE, Ayer M, Kantarcioglu B, Arica D, Demirel N, Aydin D, Yalniz FF, Elverdi T, Salihoglu A, Ar MC, Ongoren Aydin S, Baslar Z, Aydin Y, Tuzuner N, Ozbek U, Soysal T. Eskazan AE, et al. Among authors: tuzuner n. Br J Haematol. 2014 Oct;167(1):139-41. doi: 10.1111/bjh.12937. Epub 2014 May 10. Br J Haematol. 2014. PMID: 24815307 Free article. No abstract available.
Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion.
Eskazan AE, Eyice D, Kurt EA, Elverdi T, Yalniz FF, Salihoglu A, Ar MC, Ongoren Aydin S, Baslar Z, Ferhanoglu B, Aydin Y, Tuzuner N, Ozbek U, Soysal T. Eskazan AE, et al. Among authors: tuzuner n. Leuk Res. 2014 Jul;38(7):781-7. doi: 10.1016/j.leukres.2014.04.004. Epub 2014 Apr 18. Leuk Res. 2014. PMID: 24832371
Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature.
Ongoren S, Eskazan AE, Suzan V, Savci S, Erdogan Ozunal I, Berk S, Yalniz FF, Elverdi T, Salihoglu A, Erbilgin Y, Iseri SA, Ar MC, Baslar Z, Aydin Y, Tuzuner N, Ozbek U, Soysal T. Ongoren S, et al. Among authors: tuzuner n. Hematology. 2018 May;23(4):212-220. doi: 10.1080/10245332.2017.1385193. Epub 2017 Oct 9. Hematology. 2018. PMID: 28990873 Free article. Review.
74 results